Bernstein lowered the firm’s price target on Alnylam to $216 from $218 and keeps an Outperform rating on the shares. The firm notes Alnylam delivered a low quality/large quantity beat in Q3, but no one really paid attention to the results, as all eyes remain laser focused on the HELIOS-B trial reading out in early 2024.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on ALNY:
- Alnylam reports Q3 EPS $1.74, consensus ($1.36)
- ALNY Upcoming Earnings Report: What to Expect?
- Alnylam announces publication of results from Phase 3 study of patisiran
- Alnylam reports added ‘positive interim results’ from Phase 1 Alzheimer’s trial
- Biotech Alert: Searches spiking for these stocks today